BIRC5 and neoplasm: Compared to the PBT24-control, only the 10 mM NaDCA dose significantly reduced the number of survivin-positive cells in the PBT24 tumor; this dose was more effective in reducing the expression of the marker than the treatment with 5 mM NaDCA and 2.5 mM MgDCA.